1
00:00:00,000 --> 00:00:05,458
Zenagamtide, previously called amycretin, combines GLP-1 and amylin receptor activity within one

2
00:00:05,458 --> 00:00:10,125
molecule. Following both names helps keep the research record connected.

3
00:00:10,125 --> 00:00:15,208
A 2025 first-in-human randomized trial studied oral amycretin in 144 participants.

4
00:00:15,208 --> 00:00:21,083
The main questions concerned safety, tolerability, and how the body handled the compound.

5
00:00:21,083 --> 00:00:25,333
Gastrointestinal events were common, and body-weight changes were explored.

6
00:00:25,333 --> 00:00:31,583
Early findings can support further trials without establishing a complete long-term benefit and risk

7
00:00:31,583 --> 00:00:35,083
profile.

8
00:00:35,083 --> 00:00:38,958
Oral and injectable formulations have separate study histories.

9
00:00:38,958 --> 00:00:45,208
Neither a shared name nor promising early results makes their effects interchangeable or establishes

10
00:00:45,208 --> 00:00:49,083
equivalence to a product outside the clinical program.